[HTML] nature.com

[HTML][HTML] FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer

S Annett, G Moore, A Short, A Marshall… - British Journal of …, 2020 - nature.com
Background ALM201 is a therapeutic peptide derived from FKBPL that has previously
undergone preclinical and clinical development for oncology indications and has completed …
被引用次数：45 相关文章

FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer

S Annett, G Moore, A Short, A Marshall… - British Journal of …, 2020 - opus.lib.uts.edu.au
Background FKBPL is a divergent member of the FK506 binding protein (FKBP) family and a
novel therapeutic peptide derived from FKBPL, ALM201, has completed a first-in-man Phase …
[HTML] nih.gov

[HTML][HTML] FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer

S Annett, G Moore, A Short, A Marshall… - British Journal of …, 2020 - ncbi.nlm.nih.gov
Background ALM201 is a therapeutic peptide derived from FKBPL that has previously
undergone preclinical and clinical development for oncology indications and has completed …

FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer

S Annett, G Moore, A Short, A Marshall… - British Journal of …, 2020 - pure.qub.ac.uk
BACKGROUND: ALM201 is a therapeutic peptide derived from FKBPL that has previously
undergone preclinical and clinical development for oncology indications and has completed …

FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer

S Annett, G Moore, A Short, A Marshall… - British Journal of …, 2020 - wrap.warwick.ac.uk
Background ALM201 is a therapeutic peptide derived from FKBPL that has previously
undergone preclinical and clinical development for oncology indications and has completed …
[PDF] amazonaws.com

[PDF][PDF] FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer

S Annett, G Moore, A Short, A Marshall… - 2019 - pstorage-rcsi-9048708668.s3 …
BACKGROUND: ALM201 is a therapeutic peptide derived from FKBPL that has previously
undergone preclinical and clinical development for oncology indications and has completed …
[PDF] researchgate.net

[PDF][PDF] FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer

S Annett, G Moore, A Short, A Marshall, C McCrudden… - 2019 - researchgate.net
BACKGROUND: ALM201 is a therapeutic peptide derived from FKBPL that has previously
undergone preclinical and clinical development for oncology indications and has completed …
[PDF] qub.ac.uk

[PDF][PDF] FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer

S Annett, G Moore, A Short, A Marshall, C McCrudden… - 2019 - pureadmin.qub.ac.uk
BACKGROUND: ALM201 is a therapeutic peptide derived from FKBPL that has previously
undergone preclinical and clinical development for oncology indications and has completed …
[HTML] rcsi.com

[HTML][HTML] FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer.

S Annett, G Moore, A Short, A Marshall, C McCrudden… - 2021 - repository.rcsi.com
Background: ALM201 is a therapeutic peptide derived from FKBPL that has previously
undergone preclinical and clinical development for oncology indications and has completed …

FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer

S Annett, G Moore, A Short, A Marshall, C McCrudden… - 2020 - wslhd.intersearch.com.au
BACKGROUND: ALM201 is a therapeutic peptide derived from FKBPL that has previously
undergone preclinical and clinical development for oncology indications and has completed …